Ilumya Dosage/Direction for Use

This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of plaque psoriasis.
Posology: The recommended dose is 100 mg by subcutaneous injection at weeks 0, and 4 and every 12 weeks thereafter.
At the physician's discretion, in patients with high disease burden or in patients above 90 kg of body weight a dose of 200 mg may provide greater efficacy.
Consideration should be given to discontinuing treatment in patients who have shown no response after 28 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 28 weeks.
Missed dose: If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.
Special populations: Elderly: No dose adjustment is required (see Pharmacology: Pharmacokinetics under Actions).
Renal or hepatic impairment: Tildrakizumab has not been studied in these patient populations. No dose recommendations can be made. For further information on elimination of tildrakizumab, see Pharmacology: Pharmacokinetics under Actions.
Paediatric population: The safety and efficacy of tildrakizumab in children and adolescents below the age of 18 years have not yet been established. No data are available.
Method of administration: This medicinal product is administered by subcutaneous injection. Injection sites should be alternated. Tildrakizumab should not be injected into areas where the skin is affected by plaque psoriasis or is tender, bruised, red, hard, thick, or scaly. The syringe must not be shaken. Each syringe is for single use only.
After proper training in subcutaneous injection technique, patients may self-inject tildrakizumab if a physician determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Patients should be instructed to inject the full amount of tildrakizumab according to the instructions provided in the package leaflet. Comprehensive instructions for administration are given in the medication guide.